Can zinc enhance response interferon therapy for patients with HCV-related liver disease?

World Journal of Gastroenterology

Volumn 18, Issue 25, 2012, Pages 3196-3200

  Ishikawa, Toru ^a  

^a Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

Chronic hepatitis c; Interferon therapy; Zinc

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 4; INTERFERON; POLAPREZINC; RIBAVIRIN; VIRUS RNA; ZINC;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASYMPTOMATIC DISEASE; CHRONIC LIVER DISEASE; DISEASE CARRIER; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; SIDE EFFECT; SUPPLEMENTATION; TREATMENT DURATION; VIRUS GENE; VIRUS LOAD; ZINC BLOOD LEVEL; ZINC METABOLISM;

EID: 84863910136     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i25.3196     Document Type: Article

References (43)

1. Granick S. Iron metabolism and hemochromatosis. Bull N Y Acad Med 1949; 25: 403-428
2. Evans GW, Bubois RS, Hambidge KM. Wilson's disease: identification of an abnormal copper-binding protein. Science 1973; 181: 1175-1176
3. Fredricks RE, Tanaka KR, Valentine WN. Zinc in human blood cells: normal values and abnormalities associated with liver disease. J Clin Invest 1960; 39: 1651-1656
4. Herring WB, Leavell BS, Paixo LM, Yoe JH. Trace metals in human plasma and red blood cells. A study of magnesium, chromium, nickel, copper and zinc. I. Observations of normal subjects. Am J Clin Nutr 1960; 8: 846-854
5. Herring WB, Leavell BS, Paixao LM, Yoe JH. Trace metals in human plasma and red blood cells. A study of magnesium, chromium, nickel, copper and zinc. II. Observations of patients with some hematologic diseases. Am J Clin Nutr 1960; 8: 855-863
6. Vikbladh I. Studies on zinc in blood II. Scand J Clin Lab Invest 1951; 3 Suppl 2: 1-74
7. Bartholomay AF, Robin ED, Vallee RL, Wacker WE. Zinc metabolism in hepatic dysfunction. I. Serum zinc concentrations in Laënnec's cirrhosis and their validation by sequential analysis. N Engl J Med 1956; 255: 403-408
8. Sullivan JF, Jetton MM, Burch RE. A zinc tolerance test. J Lab Clin Med 1979; 93: 485-492
9. Grüngreiff K, Abicht K, Kluge M, Presser HJ, Franke D, Kleine FD, Klauck S, Diete U. Clinical studies on zinc in chronic liver diseases. Z Gastroenterol 1988; 26: 409-415
10. Solis-Herruzo J, De Cuenca B, Muñoz-Rivero MC. Intestinal zinc absorption in cirrhotic patients. Z Gastroenterol 1989; 27: 335-338
11. Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology 1988; 8: 1605-1609
12. Milman N, Laursen J, Pødenphant J, Asnaes S. Trace elements in normal and cirrhotic human liver tissue. I. Iron, copper, zinc, selenium, manganese, titanium and lead measured by X-ray fluorescence spectrometry. Liver 1986; 6: 111-117
13. Nandi SS, Chawla YK, Nath R, Dilawari JB. Serum and urinary zinc in fulminant hepatic failure. J Gastroenterol Hepatol 1989; 4: 209-213
14. Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H, Kondo F, Yukawa M. Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. Oncology 2003; 65: 323-330
15. Ebara M, Fukuda H, Saisho H. The copper/zinc ratio in patients with hepatocellular carcinoma. J Gastroenterol 2003; 38: 104-105
16. Moriyama M, Matsumura H, Fukushima A, Ohkido K, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N, Arakawa Y. Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease. Dig Dis Sci 2006; 51: 1967-1977
17. Han DS, Hahm B, Rho HM, Jang SK. Identification of the protease domain in NS3 of hepatitis C virus. J Gen Virol 1995; 76 (Pt 4): 985-993
18. Lohmann V, Koch JO, Bartenschlager R. Processing path-ways of the hepatitis C virus proteins. J Hepatol 1996; 24: 11-19
19. Stempniak M, Hostomska Z, Nodes BR, Hostomsky Z. The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol 1997; 71: 2881-2886
20. Schregel V, Jacobi S, Penin F, Tautz N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci USA 2009; 106: 5342-5347
21. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metal-loprotein. J Biol Chem 2004; 279: 48576-48587
22. Loguercio C, De Girolamo V, Federico A, Feng SL, Cataldi V, Del Vecchio Blanco C, Gialanella G. Trace elements and chronic liver diseases. J Trace Elem Med Biol 1997; 11: 158-161
23. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-1578
24. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506
25. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510
26. Nakamura H, Ito H, Ogawa H, Takeda A, Kanazawa S, Kuroda T, Yamamoto M, Enomoto H, Kimura Y, Zenda S, Terabayashi M, Saeki K, Noguchi S, Hara H, Uemiya M, Igarashi A, Hayashi E. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepatogastroenterology 1999; 46: 1131-1139
27. Iino S, Tomita E, Kumada H, Suzuki H, Toyota J, Kiyosawa K, Tanikawa K, Sata M, Hayashi N, Kakumu S, Matsushima T, Mizokami M. Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels. Hepatol Res 2005; 31: 88-94
28. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 27-34
29. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
30. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
31. Nagamine T, Takagi H, Hashimoto Y, Takayama H, Shimoda R, Nomura N, Suzuki K, Mori M, Nakajima K. The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients. Biol Trace Elem Res 1997; 58: 65-76
32. Takagi H, Nagamine T, Abe T, Takayama H, Sato K, Otsuka T, Kakizaki S, Hashimoto Y, Matsumoto T, Kojima A, Takezawa J, Suzuki K, Sato S, Mori M. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 367-371
33. Murakami Y, Koyabu T, Kawashima A, Kakibuchi N, Kawakami T, Takaguchi K, Kita K, Okita M. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 213-218
34. Boyett JD, Sullivan JF. Zinc and collagen content of cirrhotic liver. Am J Dig Dis 1970; 15: 797-802
35. Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, Yachida M, Masaki T, Kurokochi K, Watanabe S, Senda S, Kuriyama S. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scand J Gastroenterol 2007; 42: 1078-1087
36. Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, Hayashi J, Sekine N, Nirei K, Yamagami H, Ogawa M, Nakajima N, Amaki S, Tanaka N, Moriyama M. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr 2009; 45: 292-303
37. Takahashi M, Saito H, Higashimoto M, Hibi T. Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: A pilot study. Hepatol Res 2007; 37: 405-409
38. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, Warnes TW. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002; 36: 805-811
39. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol 2006; 21 Suppl 3: S34-S37
40. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003; 34: 1-10
41. Overbeck S, Rink L, Haase H. Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Arch Immunol Ther Exp (Warsz) 2008; 56: 15-30
42. Yuasa K, Naganuma A, Sato K, Ikeda M, Kato N, Takagi H, Mori M. Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int 2006; 26: 1111-1118
43. Nagamine T, Nakajima K, Takada H, Sekine Y, Suzuki K. Induction of type 1 interferon receptor by zinc in U937 cells. Cytokine 2009; 46: 346-350